Evolving Paradigms in Bladder Cancer: References

Publication
Article
Evolving ParadigmsBladder Cancer
Volume 1
Issue 1

References for Evolving Paradigms in Bladder Cancer

  1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014.CA Cancer J Clin. 2014;64(1):9-29
  2. Green D, Shariat SF. Bladder tumors: molecular aspects and clinical management.BJU Int. 2011;108(7):E163-E163.
  3. Surveillance, Epidemiology, and End Results (SEER) Program. SEER cancer statistics review 1975-2011. http://seer.cancer.gov/csr/1975_2011/. Accessed October 15, 2014.
  4. Prout GR, Barton BA, Griffin PP, Friedell GH. Treated history of noninvasive grade 1 transitional cell carcinoma. The National Bladder Cancer Group.J Urol. 1992;148(5):1413-1419.
  5. Dovedi SJ, Davies BR. Emerging targeted therapies for bladder cancer: a disease waiting for a drug.Cancer Metastasis Rev.2009;28(3-4):355-367.
  6. American Cancer Society. What is bladder cancer? http://www.cancer.org/cancer/bladdercancer/detailedguide/bladder-cancer-what-is-bladder-cancer. Accessed September 30, 2014.
  7. Bjerregaard BK, Raaschou-Nielsen O, Sørensen M, et al. Tobacco smoke and bladder cancer--in the European Prospective Investigation into Cancer and Nutrition.International J Cancer. 2006;119(10):2412-2416.
  8. Zeegers MP, Tan FE, Dorant E, van Den Brandt PA. The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies.Cancer. 2000;89(3):630-639.
  9. Cancer Treatment Centers of America. Bladder cancer risk factors. http://www.cancercenter.com/bladder-cancer/risk-factors/. Accessed September 30, 2014.
  10. MD Anderson Cancer Center. Bladder cancer prevention and screening. http://www .mdanderson.org/patient-and-cancer-information/cancer-information/cancer-types/ bladder-cancer/prevention/index.html. Accessed September 30, 2014.
  11. Bladder Cancer Advocacy Network. Understanding bladder cancer. http://www.bcan.org/ learn/understanding-bladder-cancer/. Accessed September 30, 2014.
  12. Yee DS, Ishill NM, Herr HW, Elkin EB. Ethnic differences in bladder cancer survival.Urology. 2011;78(3):544-549.
  13. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer. 2014. http://www.tri-kobe.org/nccn/guideline/urological/english/bladder. pdf. Accessed September 30, 2014.
  14. The James Buchanan Brady Urological Institute. Bladder cancer: screening and diagnosis. http://urology.jhu.edu/bladder/bladder_cancer_diagnosis.php. Accessed September 30, 2014.
  15. Cancer Treatment Centers of America. Cystoscopy for bladder cancer. http://www.cancercenter.com/bladder-cancer/cytoscopy/. Accessed September 30, 2014.
  16. McNeil BK, Ekwenna OO, Getzenberg RH. Moleclar signatures of bladder cancer. In:Bladder Tumors: Molecular Aspects and Clinical Management.2011:105-119.
  17. Black PC, Brown GA, Dinney CP. Molecular markers of urothelial cancer and their use in the monitoring of superficial urothelial cancer.J Clin Oncol. 2006;24(35):5528-5235.
  18. Sarosdy MF, Hudson MA, Ellis WJ, et al. Improved detection of recurrent bladder cancer using the Bard BTA stat Test.Urology.1997;50(3):349-353.
  19. Malkowicz SB. The application of human complement factor H-related protein (BTA TRAK) in monitoring patients with bladder cancer.Urol Clin North Am.2000;27(1):63-73, ix.
  20. Fradet Y, Lockhard C. Performance characteristics of a new monoclonal antibody test for bladder cancer: ImmunoCyt trade mark.Canadian J Urol.1997;4(3):400-405.
  21. Messing EM, Teot L, Korman H, et al. Performance of urine test in patients monitored for recurrence of bladder cancer: a multicenter study in the United States.J Urol.2005;174(4 Pt 1):1238-1241.
  22. Mian C, Lodde M, Comploj E, et al. The value of the ImmunoCyt/uCyt+ test in the detection and follow-up of carcinoma in situ of the urinary bladder.Anticancer Res.2005;(5):3641- 3644.
  23. Têtu B, Tiguert R, Harel F, Fradet Y. ImmunoCyt/uCyt+ improves the sensitivity of urine cytology in patients followed for urothelial carcinoma.Mod Pathol. 2005;18(1):83-89.
  24. Vriesema JL, Atsma F, Kiemeney LA, Peelen WP, Witjes JA, Schalken JA. Diagnostic efficacy of the ImmunoCyt test to detect superficial bladder cancer recurrence.Urology. 2001;58(3):367-371.
  25. Stec AA, Cookson MS, Chang SS. Detection of extravesical disease: a lack of bladder cancer markers. In:Bladder Cancer: Diagnosis, Therapeutics, and Management.; 2010:59-70.
  26. Skacel M, Fahmy M, Brainard JA, et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology.J Urol. 2003;169(6):2101-2105.
  27. Yoder BJ, Skacel M, Hedgepeth R, et al. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings.Am J Clin Pathol. 2007;127(2):295-301.
  28. MD Anderson Cancer Center. Bladder cancer diagnosis. http://www.mdanderson.org/ patient-and-cancer-information/cancer-information/cancer-types/bladder-cancer/diagnosis/index.html. Accessed September 30, 2014.
  29. Action on Bladder Cancer. Grading and staging of bladder cancer: how aggressive is my tumour? http://www.actiononbladdercancer.org/content.php?id=159g=2/Types. Accessed September 30, 2014.
  30. National Cancer Institute. What you need to know about bladder cancer: treatment. http:// www.cancer.gov/cancertopics/wyntk/bladder/page8. Accessed September 30, 2014.
  31. The James Buchanan Brady Urological Institute. Bladder cancer: treatments. http://urology. jhu.edu/bladder/bladder_cancer_treatments.php. Accessed September 30, 2014.
  32. American Cancer Society. Intravesical therapy for bladder cancer. http://www.cancer.org/ cancer/bladdercancer/detailedguide/bladder-cancer-treating-intravesical-therapy. Accessed September 30, 2014.
  33. 3. National Cancer Institute. Bladder cancer treatment: treatment option overview. http:// www.cancer.gov/cancertopics/pdq/treatment/bladder/Patient/page4#Keypoint20. Accessed September 30, 2014.
  34. National Cancer Institute. Bladder cancer treatment: treatment options by stage. http:// www.cancer.gov/cancertopics/pdq/treatment/bladder/Patient/page5. Accessed September 30, 2014.
  35. Clinicaltrials.gov. Phase 1/2 Study of ABI-009 in non-muscle invasive bladder cancer. http://clinicaltrials.gov/ct2/show/NCT02009332. Accessed October 5, 2014.
  36. Clinicaltrials.gov. Adaptive radiotherapy using plan selection for bladder cancer (plan selection). http://clinicaltrials.gov/ct2/show/NCT01762527. Accessed October 5, 2014.
  37. Clinicaltrials.gov. Phase I & II trial of intravesicular abraxane for treatment-refractory bladder cancer. http://clinicaltrials.gov/ct2/show/NCT00583349. Accessed October 5, 2014.
  38. Clinicaltrials.gov. Afatinib in advanced refractory urothelial cancer. http://clinicaltrials.gov/ ct2/show/NCT02122172. Accessed October 5, 2014.
  39. Clinicaltrials.gov. A study of ALT-801 in combination with cisplatin and gemcitabine in muscle invasive or metastatic urothelial cancer. http://clinicaltrials.gov/ct2/show/NCT01326871. Accessed October 1, 2014.
  40. Clinicaltrials.gov. A Study of ALT-801 in patients with bacillus calmette-guerin (BCG) failure non-muscle invasive bladder cancer. http://clinicaltrials.gov/ct2/show/NCT01625260. Accessed October 1, 2014.
  41. Clinicaltrials.gov. A study of intravesical Bacillus Calmette-Guerin (BCG) in combination with ALT-803 in patients with BCG-naive non-muscle invasive bladder cancer. http://clinicaltrials.gov/ct2/show/NCT02138734. Accessed October 5, 2014.
  42. Clinicaltrials.gov. Trial of amrubicin as second-line therapy in patients with advanced/metastatic refractory urothelial carcinoma. http://clinicaltrials.gov/ct2/show/NCT01331824. Accessed October 5, 2014.
  43. Clinicaltrials.gov. Pilot study of BC-819/PEI and BCG in patients with superficial transitional cell bladder carcinoma. http://clinicaltrials.gov/ct2/show/NCT01878188. Accessed October 5, 2014.
  44. Clinicaltrials.gov. Gemcitabine hydrochloride and cisplatin with or without bevacizumab in treating patients with advanced urinary tract cancer. http://clinicaltrials.gov/ct2/show/ NCT00942331. Accessed October 5, 2014.
  45. Clinicaltrials.gov. Buparlisib in metastatic transitional cell carcinoma of the urothelium. http://clinicaltrials.gov/ct2/show/NCT01551030. Accessed October 5, 2014.
  46. Clinicaltrials.gov. Bristol bladder trial. http://clinicaltrials.gov/ct2/show/NCT01616875. Accessed October 5, 2014.
  47. Clinicaltrials.gov. Treatment of locally advanced or metastatic transitional cell carcinoma with cabazitaxel (CabB1). http://clinicaltrials.gov/ct2/show/NCT01668459. Accessed October 5, 2014.
  48. Clinicaltrials.gov. Cabozantinib for advanced urothelial cancer. http://clinicaltrials.gov/ct2/ show/NCT01688999. Accessed October 5, 2014.
  49. Clinicaltrials.gov. Study of gemcitabine, carboplatin, and panitumumab (GCaP) as neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer. http://clinicaltrials. gov/ct2/show/NCT01916109. Accessed October 5, 2014.
  50. Clinicaltrials.gov. Clinical study of microdosing carboplatin in lung or bladder cancer. http://clinicaltrials.gov/ct2/show/NCT01261299. Accessed October 5, 2014.
  51. Clinicaltrials.gov. Carboplatin and gemcitabine hydrochloride with or without vandetanib as first-line therapy in treating patients with locally advanced or metastatic urinary tract cancer. http://clinicaltrials.gov/ct2/show/NCT01191892. Accessed October 5, 2014.
  52. Clinicaltrials.gov. A Phase 1 study of CC-486 as a single agent and in combination with carboplatin or ABI-007 in subjects with relapsed or refractory solid tumors. http://clinicaltrials.gov/ct2/show/NCT01478685. Accessed October 5, 2014.
  53. Clinicaltrials.gov. Efficacy study of recombinant adenovirus for non muscle invasive bladder cancer (BOND). http://clinicaltrials.gov/ct2/show/NCT01438112. Accessed October 5, 2014.
  54. Clinicaltrials.gov. Mechanism of action trial of ColoAd1 (MOA). http://clinicaltrials.gov/ct2/show/NCT02053220. Accessed October 5, 2014.
  55. Clinicaltrials.gov. Phase I / II study of ColoAd1 by sub-acute fractionated IV dosing in cancer patients (EVOLVE). http://clinicaltrials.gov/ct2/show/NCT02028442. Accessed October 5, 2014.
  56. Clinicaltrials.gov. Neoadjuvant dose dense gemcitabine and cisplatin (DD GC) in patients with muscle-invasive bladder cancer. http://clinicaltrials.gov/ct2/show/NCT01589094. Accessed October 5, 2014.
  57. Clinicaltrials.gov. Dovitinib in BCG refractory urothelial carcinoma with FGFR3 mutations or over-expression. http://clinicaltrials.gov/ct2/show/NCT01732107. Accessed October 5, 2014.
  58. Clinicaltrials.gov. First-line everolimus +/- paclitaxel for cisplatin-ineligible patients with advanced urothelial carcinoma. http://clinicaltrials.gov/ct2/show/NCT01215136. Accessed October 5, 2014.
  59. Clinicaltrials.gov. RAD001 and intravesical gemcitabine in BCG-refractory primary or secondary carcinoma in situ of the bladder. http://clinicaltrials.gov/ct2/show/NCT01259063. Accessed October 5, 2014.
  60. Clinicaltrials.gov. A Phase 1/2 Study of HS-410 in patients with non-muscle invasive bladder cancer after TURBT. http://clinicaltrials.gov/ct2/show/NCT02010203. Accessed October 1, 2014.
  61. Clinicaltrials.gov. Image-guided radiation therapy for bladder-cancer patients undergoing radiotherapy and concurrent gemcitabine chemotherapy. http://clinicaltrials.gov/ct2/ show/NCT01104350. Accessed October 5, 2014.
  62. Clinicaltrials.gov. Image-Guided Tumorboost of Bladder Cancer. http://clinicaltrials.gov/ct2/ show/NCT00963404. Accessed October 5, 2014.
  63. Clinicaltrials.gov. First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma. http://clinicaltrials.gov/ct2/show/NCT01524991. Accessed October 5, 2014.
  64. Clinicaltrials.gov. A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors. http:// clinicaltrials.gov/ct2/show/NCT01928394. Accessed October 1, 2014.
  65. Clinicaltrials.gov. Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/ Metastatic Urothelial Cancer and Other Solid Tumors. http://clinicaltrials.gov/ct2/show/ NCT01352962. Accessed October 5, 2014.
  66. Clinicaltrials.gov. Safety and Efficacy Study of Cancer Immunotherapeutic MAGE-A3 + AS-15 in Patients With Muscle-invasive Bladder Cancer After Cystectomy (MAGNOLIA). http://clinicaltrials.gov/ct2/show/NCT01435356. Accessed October 5, 2014.
  67. Clinicaltrials.gov. Methotrexate, Vinblastine, Doxorubicin and Cisplatin (MVAC) Followed by Gemcitabine Plus Cisplatin (GEM+CDDP) in Locally Advanced or Metastatic Bladder Cancer. http://clinicaltrials.gov/ct2/show/NCT00635726. Accessed October 5, 2014.
  68. Clinicaltrials.gov. Fluorescence Cystoscopy and Optimized MMC in Recurrent Bladder Cancer (FinnBladder 9). http://clinicaltrials.gov/ct2/show/NCT01675219. Accessed October 5, 2014.
  69. Clinicaltrials.gov. A Study of MPDL3280A in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer. http://clinicaltrials.gov/ct2/show/NCT02108652. Accessed October 5, 2014.
  70. Clinicaltrials.gov. NUC-1031 in Patients With Advanced Solid Tumours (ProGem1). http:// clinicaltrials.gov/ct2/show/NCT01621854. Accessed October 5, 2014.
  71. Clinicaltrials.gov. Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer. http://clinicaltrials.gov/ct2/show/NCT01780545. Accessed October 5, 2014.
  72. Clinicaltrials.gov. Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG. http://clinicaltrials.gov/ct2/show/NCT02015104. Accessed October 5, 2014.
  73. Clinicaltrials.gov. Study With Pazopanib in Combination With Cisplatin (CDDP) in Patients With Advanced Solid Tumors (PACIFIK). http://clinicaltrials.gov/ct2/show/NCT01165385. Accessed October 5, 2014.
  74. Clinicaltrials.gov. Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer. http://clinicaltrials.gov/ct2/show/NCT01108055. Accessed October 1, 2014.
  75. Clinicaltrials.gov. A Phase II Trial Evaluating an Organ-conserving Strategy by Radiochemotherapy for Muscle-infiltrative Bladder Cancer (GETUG V04). http://clinicaltrials.gov/ct2/ show/NCT01495676. Accessed October 5, 2014.
  76. Clinicaltrials.gov. Radiation Therapy After Surgery in Treating Patients With High-Risk Bladder Cancer. http://clinicaltrials.gov/ct2/show/NCT01954173. Accessed October 5, 2014.
  77. Clinicaltrials.gov. Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer. http://clinicaltrials.gov/ct2/show/NCT00981656. Accessed October 5, 2014.
  78. Clinicaltrials.gov. Neoadjuvant Rapamycin in Patients Undergoing Radical Cystectomy. http://clinicaltrials.gov/ct2/show/NCT01827618. Accessed October 5, 2014.
  79. Clinicaltrials.gov. Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer. http://clinicaltrials.gov/ct2/show/NCT01938573. Accessed October 5, 2014.
  80. Clinicaltrials.gov. Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract (VINSOR). http://clinicaltrials.gov/ct2/ show/NCT01844947. Accessed October 5, 2014.
  81. Clinicaltrials.gov. Phase II Evaluating Efficacy of Temsirolimus in 2 Line Therapy for Patients With Advanced Bladder Cancer (VESTOR). http://clinicaltrials.gov/ct2/show/ NCT01827943. Accessed October 1, 2014.
  82. Clinicaltrials.gov. 3-Dimensional Conformal Radiation Therapy in Treating Patients With Bladder Cancer Who Have Undergone Transurethral Resection of the Bladder. http://clinicaltrials.gov/ct2/show/NCT01124682. Accessed October 5, 2014.
  83. Clinicaltrials.gov. 3 Tesla MRI in Patients With Bladder Cancer. http://clinicaltrials.gov/ct2/ show/NCT00938145. Accessed October 5, 2014.
  84. Habuchi T. Prognostic markers for bladder cancer. In:Bladder Tumors: Molecular Aspects and Clinical Management. 2011:139-163.
  85. Inman BA, Sebo TJ, Frigola X, et al. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.Cancer. 2007;109(8):1499-1505.
  86. Boorjian SA, Sheinin Y, Crispen PL, et al. T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival.Clin Cancer Res.2008;14(15):4800-4808.
  87. Nakanishi J, Wada Y, Matsumoto K, Azuma M, Kikuchi K, Ueda S. Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers.Cancer Immunol Immunother. 2007;56(8):1173-1182.
  88. Wang Y, Zhuang Q, Zhou S, Hu Z, Lan R. Costimulatory molecule B7-H1 on the immune escape of bladder cancer and its clinical significance.J Huazhong Univ Sci Technolog Med Sci. 2009;29(1):77-79.
  89. Xylinas E, Robinson BD, Kluth LA, et al. Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder.Eur J Surg Oncol. 2014;40(1):121-127.
  90. Powles T, Vogelzang NJ, Fine GD, et al. Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC).J Clin Oncol.2014;32(5s). Abstract 5011.
  91. Myers-Irvin JM, Van Le T-S, Getzenberg RH. Mechanistic analysis of the role of BLCA-4 in bladder cancer pathobiology.Cancer Res. 2005;65(16):7145-7150.
  92. Cong Y-S, Wright WE, Shay JW. Human telomerase and its regulation.Microbiol Mol Biol Rev. 2002;66(3):407-425.
  93. Zachos I, Konstantinopoulos PA, Vandoros GP, et al. Predictive value of telomerase reverse transcriptase expression in patients with high risk superficial bladder cancer treated with adjuvant BCG immunotherapy.J Cancer Res Clin Oncol. 2009;135(9):1169-1175.
  94. Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Altieri DC. Urine detection of survivin and diagnosis of bladder cancer.JAMA. 2001;285(3):324-328.
  95. Shariat SF, Casella R, Khoddami SM, et al. Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer.J Urol.2004;171(2, pt 1):626-630.
  96. Davies B, Chen J, Modugno F, et al. Contribution of the prostate limits the usefulness of survivin for the detection of bladder cancer.J Urol.2005;174(5):1767-1770.
  97. di Martino E, Tomlinson DC, Knowles MA. A decade of FGF receptor research in bladder cancer: past, present, and future challenges.Adv Urol. 2012;2012:429213.
  98. Kanayama H, Yokota K, Kurokawa Y, Murakami Y, Nishitani M, Kagawa S. Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer.Cancer. 1998;82(7):1359-1366.
  99. Gohji K, Fujimoto N, Ohkawa J, Fujii A, Nakajima M. Imbalance between serum matrix metalloproteinase-2 and its inhibitor as a predictor of recurrence of urothelial cancer.Br J Cancer. 1998;77(4):650-655.
  100. Gallagher DJ, Milowsky MI, Gerst SR, et al. Phase II study of sunitinib in patients with metastatic urothelial cancer.J Clin Oncol. 2010;28(8):1373-1379.
  101. Clinicaltrials.gov. Bacillus Calmette-Guerin followed by sunitinib for the treatment of high risk non-muscle invasive lower urinary tract urothelial carcinoma (Sutent). http://clinicaltrials.gov/ct2/show/NCT00794950?term=bladder+cancer+AND+Sunitinib&rank=10. Accessed October 1, 2014.
  102. Clinicaltrials.gov. Cabozantinib for advanced urothelial cancer. http://clinicaltrials.gov/ct2/ show/NCT01688999. Accessed October 1, 2014.
  103. Clinicaltrials.gov. Alisertib in chemotherapy-pretreated urothelial cancer. http://clinicaltrials.gov/ct2/show/NCT02109328. Accessed October 1, 2014.
  104. Clinicaltrials.gov. Erlotinib hydrochloride in treating patients with bladder cancer undergoing surgery. http://clinicaltrials.gov/ct2/show/NCT02169284. Accessed October 1, 2014.
  105. Clinicaltrials.gov. Afatinib in advanced refractory urothelial cancer. http://clinicaltrials.gov/ ct2/show/NCT02122172. Accessed October 1, 2014.
  106. Clinicaltrials.gov. Dovitinib in BCG refractory urothelial carcinoma with FGFR3 mutations or over-expression. http://clinicaltrials.gov/ct2/show/NCT01732107. Accessed October 1, 2014.
  107. Clinicaltrials.gov. Study of gemcitabine, carboplatin, and panitumumab (GCaP) as neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer. http://clinicaltrials .gov/ct2/show/NCT01916109. Accessed October 1, 2014.
  108. Clinicaltrials.gov. First-line everolimus +/- paclitaxel for cisplatin-ineligible patients with advanced urothelial carcinoma. http://clinicaltrials.gov/ct2/show/NCT01215136. Accessed October 1, 2014.
  109. Clinicaltrials.gov. Gemcitabine and split-dose cisplatin plus everolimus (RAD001) in patients with advanced solid tumor malignancies. http://clinicaltrials.gov/ct2/show/ NCT01182168. Accessed October 1, 2014.
  110. Clinicaltrials.gov. RAD001 and intravesical gemcitabine in BCG-refractory primary or secondary carcinoma in situ of the bladder. http://clinicaltrials.gov/ct2/show/NCT01259063. Accessed October 1, 2014.
  111. Clinicaltrials.gov. First-line gemcitabine, cisplatin + ipilimumab for metastatic urothelial carcinoma. http://clinicaltrials.gov/ct2/show/NCT01524991. Accessed October 1, 2014.
  112. Clinicaltrials.gov. Dose-escalation study of CG0070 for bladder cancer after BCG (Bacillus Calmette-Guerin) failure. http://clinicaltrials.gov/ct2/show/NCT00109655. Accessed October 1, 2014.
  113. Clinicaltrials.gov. Efficacy study of recombinant adenovirus for non muscle invasive bladder cancer (BOND). http://clinicaltrials.gov/ct2/show/NCT01438112. Accessed October 1, 2014.
  114. Clinicaltrials.gov. Vaccine therapy with or without sirolimus in treating patients with NYESO-1 expressing solid tumors. http://clinicaltrials.gov/ct2/show/NCT01522820. Accessed October 1, 2014.
  115. Clinicaltrials.gov. Study of Bacillus Calmette-Guerin (BCG) combined with PANVAC versus BCG alone in adults with high grade non-muscle invasive bladder cancer who failed at least 1 course of BCG. http://clinicaltrials.gov/ct2/show/NCT02015104. Accessed October 1, 2014.
  116. Clinicaltrials.gov. Safety and efficacy study of cancer immunotherapeutic MAGE-A3 + AS- 15 in patients with muscle-invasive bladder cancer after cystectomy (MAGNOLIA). http:// clinicaltrials.gov/ct2/show/NCT01435356. Accessed October 1, 2014.
  117. Clinicaltrials.gov. Biomarker discovery and application in bladder cancer. http://clinicaltrials.gov/ct2/show/NCT00962052. Accessed October 1, 2014.
  118. Clinicaltrials.gov. Improving clinical staging for muscle invasive bladder cancer through molecular profiling and improved imaging. http://clinicaltrials.gov/ct2/show/ NCT02203136. Accessed October 1, 2014.
  119. Clinicaltrials.gov. Biomarker identification for bladder cancer patients. http://clinicaltrials .gov/ct2/show/NCT02053662. Accessed October 1, 2014.
  120. Clinicaltrials.gov. PET/MRI and biomarkers in bladder cancer (ACEBIB). http://clinicaltrials.gov/ct2/show/NCT01918592. Accessed October 1, 2014.
Articles in this issue
Other Factors Affecting Prognosis and Treatment in Bladder Cancer
Other Factors Affecting Prognosis and Treatment in Bladder Cancer
Emerging Biomarkers for Bladder Cancer
Emerging Biomarkers for Bladder Cancer
Emerging Therapies in Clinical Trials for Bladder Cancer
Emerging Therapies in Clinical Trials for Bladder Cancer
Evolving Paradigms in Bladder Cancer: Conclusion
Evolving Paradigms in Bladder Cancer: Conclusion
Introduction: Evolving Paradigms in Bladder Cancer
Introduction: Evolving Paradigms in Bladder Cancer
Current Bladder Cancer Treatment Strategies Based Upon Stage
Current Bladder Cancer Treatment Strategies Based Upon Stage
Evolving Paradigms in Bladder Cancer: References
Evolving Paradigms in Bladder Cancer: References
Recent Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
Related Content
FGFR-Altered NMIBC Treatment Advances With TAR-210 Findings

FGFR-Altered NMIBC Treatment Advances With TAR-210 Findings

Jordyn Sava
November 21st 2024
Article

In an interview, Antoni Vilaseca Cabo, MD, discussed the clinical activity of TAR-210 in patients with non-muscle invasive bladder cancer.

Read More

Forde Discusses AE Management With Dual Checkpoint Inhibition Plus Chemotherapy in NSCLC

Forde Discusses AE Management With Dual Checkpoint Inhibition Plus Chemotherapy in NSCLC

Targeted Oncology Staff
November 16th 2024
Article

During a Case-Based Roundtable® event, Patrick M. Forde, MD, discussed safety and tolerability concerns with immunotherapy in patients with squamous non–small cell lung cancer.

Read More

Learning From a Multidisciplinary Approach in Graft-Vs-Host Disease

Learning From a Multidisciplinary Approach in Graft-Vs-Host Disease

Jonah Feldman
November 15th 2024
Article

In this feature, Memorial Sloan Kettering Cancer Center physicians explain what drives the collaborative process in their multidisciplinary graft-vs-host disease clinic.

Read More

Campbell Surveys Participants on Favorable-Risk Frontline Approach in RCC

Campbell Surveys Participants on Favorable-Risk Frontline Approach in RCC

Targeted Oncology Staff
November 14th 2024
Article

During a Case-Based Roundtable® event, Matthew Campbell, MD, MS, moderated a discussion on treatment for a 61-year-old patient with lung-metastatic renal cell carcinoma.

Read More

Fellow's Perspective: Patient Case of Newly Diagnosed Multiple Myeloma

Fellow's Perspective: Patient Case of Newly Diagnosed Multiple Myeloma

Targeted Oncology Staff
November 13th 2024
Article

In a discussion with Peers & Perspectives in Oncology, fellowship program director Marc J. Braunstein, MD, PhD, FACP, and hematology/oncology fellow Olivia Main, MD, talk about their choices for a patient with transplant-eligible multiple myeloma and the data behind their decisions.

Read More

Nivolumab-Chemotherapy Combo Boosts PFS in cHL, Poised for Standard Use

Nivolumab-Chemotherapy Combo Boosts PFS in cHL, Poised for Standard Use

Morgan Bayer
November 12th 2024
Article

The N-AVD regimen showed improved progression-free survival and lower toxicity than BV-AVD in advanced Hodgkin lymphoma, particularly benefiting patients 60 and older.

Read More